公开(公告)号：US09321748B2

公开(公告)日：2016-04-26

申请号：US14758884

申请日：2013-12-30

Applicant: H. Lundbeck A/S ,  Vernalis (R&D) Ltd.

Inventor： Gitte Kobberøe Mikkelsen ,  Laurent David ,  Stephen Watson ,  Garrick Paul Smith ,  Douglas Stewart Williamson ,  I-Jen Chen

IPC: C07D401/04 ,  C07D401/14 ,  C07D403/14 ,  C07D413/04 ,  C07D413/14

CPC classification number: A61K31/5377 ,  A61K31/4439 ,  A61K31/4545 ,  A61K31/497 ,  C07D401/04 ,  C07D401/14 ,  C07D403/14 ,  C07D413/04 ,  C07D413/14

Abstract: The present invention is directed to aminopyridine derived compounds of formula (A). The compounds are considered useful for the treatment of diseases associated with LRRK2 such a Lewy body dementia, Parkinson's disease or cancer.

公开(公告)号：US12129289B2

公开(公告)日：2024-10-29

申请号：US17399205

申请日：2021-08-11

Applicant: H. Lundbeck A/S

Inventor： Jan Torleif Pedersen ,  Kristian Kjaergaard ,  Lars Østergaard Pedersen ,  Ayodeji Abdur-Rasheed Asuni ,  Nina Helen Rosenqvist ,  Justus Claus Alfred Daechsel ,  Karsten Juhl ,  Lena Tagmose ,  Mauro Marigo ,  Thomas Jensen ,  Søren Christensen ,  Laurent David ,  Christiane Volbracht ,  Lone Helboe

IPC: C07K16/18 ,  A61K39/395 ,  A61K49/00 ,  G01N33/68 ,  A61K39/00

CPC classification number: C07K16/18 ,  A61K39/395 ,  A61K49/00 ,  G01N33/6896 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/30 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/565 ,  C07K2317/75 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94 ,  G01N2800/2814 ,  G01N2800/2821

Abstract: The present invention relates to a class of monoclonal antibody that specifically binds the phosphorylated serine 396 residue on pathological hyperphosphorylated (PHF) tau (pS396) with improved affinity, as well as to methods of using these molecules and their tau binding fragments in the treatment of Alzheimer's disease and other tauopathies.

公开(公告)号：US10647762B2

公开(公告)日：2020-05-12

申请号：US16371902

申请日：2019-04-01

Applicant: H. Lundbeck A/S

Inventor： Jan Torleif Pedersen ,  Kristian Kjaergaard ,  Lars Østergaard Pedersen ,  Abdur-Rasheed Asuni ,  Nina Helen Rosenqvist ,  Justus Claus Daechsel ,  Karsten Juhl ,  Lena Tagmose ,  Mauro Marigo ,  Thomas Jensen ,  Søren Christensen ,  Laurent David ,  Christiane Volbracht ,  Lone Helboe

IPC: C07K16/18 ,  A61K49/00 ,  A61K39/395 ,  A61K39/00 ,  G01N33/68

Abstract: The present invention relates to a class of monoclonal antibody that specifically binds the phosphorylated serine 396 residue on pathological hyperphosphorylated (PHF) tau (pS396) with improved affinity, as well as to methods of using these molecules and their tau binding fragments in the treatment of Alzheimer's disease and other tauopathies.

公开(公告)号：US20190284266A1

公开(公告)日：2019-09-19

申请号：US16371902

申请日：2019-04-01

Applicant: H. Lundbeck A/S

Inventor： Jan Torleif Pedersen ,  Kristian Kjaergaard ,  Lars Østergaard Pedersen ,  Abdur-Rasheed Asuni ,  Nina Helen Rosenqvist ,  Justus Claus Daechsel ,  Karsten Juhl ,  Lena Tagmose ,  Mauro Marigo ,  Thomas Jensen ,  Søren Christensen ,  Laurent David ,  Christiane Volbracht ,  Lone Helboe

IPC: C07K16/18 ,  A61K39/395 ,  A61K49/00 ,  G01N33/68

Abstract: The present invention relates to a class of monoclonal antibody that specifically binds the phosphorylated serine 396 residue on pathological hyperphosphorylated (PHF) tau (pS396) with improved affinity, as well as to methods of using these molecules and their tau binding fragments in the treatment of Alzheimer's disease and other tauopathies.

公开(公告)号：US20150336942A1

公开(公告)日：2015-11-26

申请号：US14758884

申请日：2013-12-30

Applicant: H. Lundbeck A/S ,  Vernalis (R&D) Ltd.

Inventor： Gitte Kobberøe Mikkelsen ,  Laurent David ,  Stephen Watson ,  Garrick Paul Smith ,  Douglas Stewart Williamson ,  I-Jen Chen

IPC: C07D413/14 ,  C07D403/14

CPC classification number: A61K31/5377 ,  A61K31/4439 ,  A61K31/4545 ,  A61K31/497 ,  C07D401/04 ,  C07D401/14 ,  C07D403/14 ,  C07D413/04 ,  C07D413/14

Abstract: The present invention is directed to aminopyridine derived compounds of formula (A). The compounds are considered useful for the treatment of diseases associated with LRRK2 such a Lewy body dementia, Parkinson's disease or cancer.

Abstract translation: 本发明涉及氨基吡啶衍生的式（A）化合物。 该化合物被认为可用于治疗与LRRK2相关的疾病如路易体痴呆，帕金森病或癌症。

公开(公告)号：US20220213117A1

公开(公告)日：2022-07-07

申请号：US17583333

申请日：2022-01-25

Applicant: H. Lundbeck A/S

Inventor： John Paul Kilburn ,  Erhad Ascic ,  Mauro Marigo ,  Laurent David

IPC: C07D495/04

Abstract: The present invention is directed to novel prodrugs of modulators of the NMDA receptor. Separate aspects of the inventions are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat neurological disorders or neuropsychiatric disorders such as depression.

公开(公告)号：US11358971B2

公开(公告)日：2022-06-14

申请号：US16916681

申请日：2020-06-30

Applicant: H. Lundbeck A/S

Inventor： John Paul Kilburn ,  Erhad Ascic ,  Mauro Marigo ,  Laurent David

IPC: C07D495/04

Abstract: The present invention is directed to novel prodrugs of modulators of the NMDA receptor. Separate aspects of the inventions are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat neurological disorders or neuropsychiatric disorders such as depression.

公开(公告)号：US20210002292A1

公开(公告)日：2021-01-07

申请号：US16916769

申请日：2020-06-30

Applicant: H. Lundbeck A/S

Inventor： John Paul Kilburn ,  Erhad Ascic ,  Mauro Marigo ,  Laurent David

IPC: C07D495/04

Abstract: The present invention is directed to novel modulators of the NMDA receptor. Separate aspects of the inventions are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat neurological disorders or neuropsychiatric disorders such as depression.

公开(公告)号：US10195186B2

公开(公告)日：2019-02-05

申请号：US15584425

申请日：2017-05-02

Applicant: H. Lundbeck A/S

Inventor： Philip James Maltas ,  Stephen Watson ,  Morten Langgård ,  Laurent David

IPC: A61K31/44 ,  C07D213/75 ,  C07D215/38 ,  C07D333/66 ,  C07D401/04 ,  C07D403/04 ,  C07D237/20 ,  C07D239/42 ,  C07D241/20 ,  C07D277/46 ,  C07D213/40 ,  C07D409/04 ,  A61K31/4402 ,  A61K31/4406 ,  C07D417/04 ,  C07D213/60 ,  C07D213/65 ,  C07D333/68 ,  A61K31/381 ,  A61K31/426 ,  A61K31/47 ,  A61K31/4965 ,  A61K31/50 ,  A61K31/505

Abstract: The present invention is directed to N-substituted-5-substituted phthalamic acids which of formula (A). The compounds are considered useful for the treatment of diseases treatment of a neurodegenerative disease, psychiatric disease, motoneuron disease, peripheral neuropathies, pain, neuroinflammation or atherosclerosis such as Alzheimer's disease and Parkinson's disease.

公开(公告)号：US20180016330A1

公开(公告)日：2018-01-18

申请号：US15645442

申请日：2017-07-10

Applicant: H. Lundbeck A/S

Inventor： Jan Torleif Pedersen ,  Kristian Kjærgaard ,  Lars Østergaard Pedersen ,  Abdur-Rasheed Asuni ,  Nina Helen Rosenqvist ,  Justus Claus Alfred Daechsel ,  Karsten Juhl ,  Lena Tagmose ,  Mauro Marigo ,  Thomas Jensen ,  Søren Christensen ,  Laurent David ,  Christiane Volbracht ,  Lone Helboe

IPC: C07K16/18 ,  A61K39/00

Abstract: The present invention relates to a class of monoclonal antibody that specifically binds the phosphorylated serine 396 residue on pathological hyperphosphorylated (PHF) tau (pS396) with improved affinity, as well as to methods of using these molecules and their tau binding fragments in the treatment of Alzheimer's disease and other tauopathies.